TransMedics Group (TMDX, Financial) experienced a sharp decline in its stock price today, falling over 15% following the release of a critical report by Scorpion Capital. The report accuses the company of engaging in unethical practices, including "mafia-style" extortion, racketeering, and organ trafficking schemes, all under the guise of a medical device company. Scorpion Capital has set a target price of $0 for TransMedics, indicating a belief that the company's shares are worthless.
The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and widespread off-label misuse of its Organ Care System (OCS).
In response to these allegations, Scorpion Capital announced plans to file a Citizen Petition with the FDA, requesting the suspension of Premarket Approval (PMA) for TransMedics' OCS. They also intend to send a public letter to members of Congress probing abuses in the U.S. organ transplant system.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.